Tatva Chintan Pharma Chem Limited (NSE:TATVA)

Market Cap	27.71B +46.6%
Revenue (ttm)	4.80B +28.5%
Net Income	327.63M +129.2%
EPS	14.02 +129.6%
Shares Out	23.39M
PE Ratio	84.52
Forward PE	45.15
Dividend	1.00 (0.08%)
Ex-Dividend Date	Sep 12, 2025

Volume	24,588
Average Volume	129,663
Open	1,183.00
Previous Close	1,184.70
Day's Range	1,180.00 - 1,228.90
52-Week Range	621.00 - 1,610.00
Beta	0.22
RSI	45.58
Earnings Date	Jan 21, 2026

About Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal car...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1996
• Employees: 679
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: TATVA

Financial Performance

In fiscal year 2025, Tatva Chintan Pharma Chem's revenue was 3.83 billion, a decrease of -2.74% compared to the previous year's 3.94 billion. Earnings were 57.13 million, a decrease of -81.18%.